What the FDA labels say about taking them together
Clopidogrel and selexipag
Selexipag's FDA label of May 28, 2026 names clopidogrel in its drug interactions section; the clopidogrel label PlainMeds reads does not name selexipag. The selexipag label: “DRUG INTERACTIONS Moderate CYP2C8 inhibitors increase exposure to the active metabolite of UPTRAVI.”
Check it at the source: the clopidogrel FDA label on DailyMed (effective May 30, 2025, Sanofi-Aventis U.S. LLC); the selexipag FDA label on DailyMed (effective May 28, 2026, Actelion Pharmaceuticals US, Inc.).
What does the clopidogrel label say about selexipag?
Clopidogrel's label (effective May 30, 2025) does not name selexipag in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Plavix), Sanofi-Aventis U.S. LLC, effective May 30, 2025 (SPL set de8b0b67-eb25-4684-83b5-7ad785314227), via openFDA; the full label on DailyMed
What does the selexipag label say about clopidogrel?
Selexipag label, drug interactionsDRUG INTERACTIONS Moderate CYP2C8 inhibitors (e.g., clopidogrel, deferasirox and teriflunomide) increase exposure to the active metabolite of UPTRAVI.
Source: FDA drug label (UPTRAVI), Actelion Pharmaceuticals US, Inc., effective May 28, 2026 (SPL set a7a23b87-f892-4e2c-8e2e-ebf841220f90), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Clopidogrel | Selexipag | |
|---|---|---|
| Labeled for | Heart attack and coronary artery disease, Angina | Pulmonary arterial hypertension |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.0472 per tablet 75 mg tablet | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once